医学
心房颤动
临床终点
左心耳阻塞
内科学
抗血栓
冲程(发动机)
随机对照试验
大出血
心脏病学
养生
外科
华法林
机械工程
工程类
作者
Ahmed Ibrahim,Laila Shalabi,Sofian Zreigh,Shrouk Ramadan,Sohaila Mourad,Ghaith Y. Eljadid,Mohammed S. Beshr,Ali Abdelaziz,Muhammed Elhadi,Pierre Sabouret,Mamas A. Mamas
摘要
ABSTRACT Background Left atrial appendage occlusion (LAAO) is an alternative to chronic oral anticoagulation (OAT) for stroke prevention in nonvalvular atrial fibrillation (NVAF) patients with contraindications to OAT. Postprocedure antithrombotic therapy (ATT) is essential to reduce the risk of device‐related thrombosis (DRT), but the optimal regimen remains uncertain. Aims This study aims to compare the safety and efficacy of low‐dose direct oral anticoagulants (DOACs) versus dual antiplatelet therapy (DAPT) following LAAO. Methods A comprehensive search of PubMed, Scopus, Cochrane, and Web of Science was conducted in August 2024. Studies comparing low‐dose DOACs and DAPT post‐LAAO were included. The primary outcomes were a composite efficacy endpoint (DRT, strokes, and systemic embolism [SE]) and major bleeding events as the safety endpoint. Secondary outcomes included all bleeding events, all‐cause mortality, and a composite of efficacy and safety endpoints. Results Four studies with 727 patients were included. Low‐dose DOACs were associated with lower rates of the primary composite efficacy endpoint compared to DAPT (OR = 0.36; 95% CI [0.16, 0.85], p = 0.01). No significant difference in major bleeding events was observed (OR = 0.36; 95% CI [0.11, 1.18]; p = 0.091; I ² = 0%). Compared to DAPT, low‐dose DOACs were also associated with lower rates of DRT events (OR = 0.36; 95% CI [0.16, 0.79], p = 0.011). Conclusion Low‐dose DOACs effectively reduce thromboembolic events post‐LAAO without increasing bleeding risk. These findings support their use as a viable ATT option, but larger trials are needed to confirm optimal regimens.
科研通智能强力驱动
Strongly Powered by AbleSci AI